Antibody Response After a Fifth Dose (Third Booster) of BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers
Abstract
1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Bar-On, Y.M.; Goldberg, Y.; Mandel, M.; Bodenheimer, O.; Freedman, L.; Kalkstein, N.; Mizrahi, B.; Alroy-Preis, S.; Ash, N.; Milo, R.; et al. Protection of BNT162b2 Vaccine Booster against COVID-19 in Israel. N. Engl. J. Med. 2021, 385, 1393–1400. [Google Scholar] [CrossRef] [PubMed]
- Saiag, E.; Goldshmidt, H.; Sprecher, E.; Ben-Ami, R.; Bomze, D. Immunogenicity of a BNT162b2 vaccine booster in health-care workers. Lancet Microbe 2021, 2, e650. [Google Scholar] [CrossRef] [PubMed]
- Bomze, D.; Sprecher, E.; Gamzu, R. Effect of a nationwide booster vaccine rollout in Israel on SARS-CoV-2 infection and severe illness in young adults. Travel Med. Infect. Dis. 2021, 44, 102195. [Google Scholar] [CrossRef] [PubMed]
- Saiag, E.; Grupper, A.; Avivi, I.; Elkayam, O.; Ram, R.; Herishanu, Y.; Cohen, Y.; Perry, C.; Furer, V.; Katchman, H.; et al. The effect of a third-dose BNT162b2 vaccine on anti-SARS-CoV-2 antibody levels in immunosuppressed patients. Clin. Microbiol. Infect. 2022, 28, 735.e5–735.e8. [Google Scholar] [CrossRef]
- Arbel, R.; Sergienko, R.; Friger, M.; Peretz, A.; Beckenstein, T.; Yaron, S.; Netzer, D.; Hammerman, A. Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years. Nat. Med. 2022, 28, 1486–1490. [Google Scholar] [CrossRef]
- Khoury, D.S.; Docken, S.S.; Subbarao, K.; Kent, S.J.; Davenport, M.P.; Cromer, D. Predicting the efficacy of variant-modified COVID-19 vaccine boosters. Nat. Med. 2023, 29, 574–578. [Google Scholar] [CrossRef]
- Kristiansen, P.A.; Page, M.; Bernasconi, V.; Mattiuzzo, G.; Dull, P.; Makar, K.; Plotkin, S.; Knezevic, I. WHO International Standard for anti-SARS-CoV-2 immunoglobulin. Lancet 2021, 397, 1347–1348. [Google Scholar] [CrossRef]
- Abedon, A.T.; Teles, M.S.; Alejo, J.L.; Kim, J.D.B.; Mitchell, J.M.; Chiang, T.P.Y.; Avery, R.K.; Tobian, A.A.R.; Levan, M.L.J.; Warren, D.S.; et al. Improved Antibody Response After a Fifth Dose of a SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series. Transplantation 2022, 106, e262–e263. [Google Scholar] [CrossRef]
- Vergori, A.; Matusali, G.; Lepri, A.C.; Cimini, E.; Fusto, M.; Colavita, F.; Gagliardini, R.; Notari, S.; Mazzotta, V.; Mariotti, D.; et al. Neutralizing activity T-cell response after bivalent fifth dose of messenger RNA vaccine in people living with HIV. Int. J. Infect. Dis. 2023, 134, 195–199. [Google Scholar] [CrossRef]
- Smeets, J.J.H.; Van Malenstein, H.; Van Der Merwe, S.; Nevens, F.; Verbeek, J. SARS-CoV-2 anti-spike IgG antibodies are present in all liver transplant recipients after fifth vaccine dose. J. Hepatol. 2024, 80, e284–e286. [Google Scholar] [CrossRef]
- Tani, Y.; Takita, M.; Wakui, M.; Saito, H.; Nishiuchi, T.; Zhao, T.; Yamamoto, C.; Kawamura, T.; Sugiyama, A.; Nakayama, A.; et al. Five doses of the mRNA vaccination potentially suppress ancestral-strain stimulated SARS-CoV2-specific cellular immunity: A cohort study from the Fukushima vaccination community survey, Japan. Front. Immunol. 2023, 14, 1240425. [Google Scholar] [CrossRef] [PubMed]
- Gao, F.-X.; Wu, R.-X.; Shen, M.-Y.; Huang, J.-J.; Li, T.-T.; Hu, C.; Luo, F.-Y.; Song, S.-Y.; Mu, S.; Hao, Y.-N.; et al. Extended SARS-CoV-2 RBD booster vaccination induces humoral and cellular immune tolerance in mice. iScience 2022, 25, 105479. [Google Scholar] [CrossRef] [PubMed]
- Minervina, A.A.; Pogorelyy, M.V.; Kirk, A.M.; Crawford, J.C.; Allen, E.K.; Chou, C.-H.; Mettelman, R.C.; Allison, K.J.; Lin, C.-Y.; Brice, D.C.; et al. SARS-CoV-2 antigen exposure history shapes phenotypes and specificity of memory CD8+ T cells. Nat. Immunol. 2022, 23, 781–790. [Google Scholar] [CrossRef] [PubMed]
- Munro, A.P.S.; Feng, S.; Janani, L.; Cornelius, V.; Aley, P.K.; Babbage, G.; Baxter, D.; Bula, M.; Cathie, K.; Chatterjee, K.; et al. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): A multicentre, blinded, phase 2, randomised trial. Lancet Infect. Dis. 2022, 22, 1131–1141. [Google Scholar] [CrossRef]
- Saiag, E.; Marudi, O.; Cohen, N.; Goldiner, I.; Ben-Ami, R.; Sprecher, E.; Bomze, D. Anti-SARS-CoV-2 antibody levels after four BNT162b2 vaccine doses among health-care workers. Travel Med. Infect. Dis. 2022, 50, 102429. [Google Scholar] [CrossRef]
- Regev-Yochay, G.; Gonen, T.; Gilboa, M.; Mandelboim, M.; Indenbaum, V.; Amit, S.; Meltzer, L.; Asraf, K.; Cohen, C.; Fluss, R.; et al. Efficacy of a Fourth Dose of COVID-19 mRNA Vaccine against Omicron. N. Engl. J. Med. 2022, 386, 1377–1380. [Google Scholar] [CrossRef]
- Magen, O.; Waxman, J.G.; Makov-Assif, M.; Vered, R.; Dicker, D.; Hernán, M.A.; Lipsitch, M.; Reis, B.Y.; Balicer, R.D.; Dagan, N. Fourth Dose of BNT162b2 mRNA COVID-19 Vaccine in a Nationwide Setting. N. Engl. J. Med. 2022, 386, 1603–1614. [Google Scholar] [CrossRef]
- Bar-On, Y.M.; Goldberg, Y.; Mandel, M.; Bodenheimer, O.; Amir, O.; Freedman, L.; Alroy-Preis, S.; Ash, N.; Huppert, A.; Milo, R. Protection by a Fourth Dose of BNT162b2 against Omicron in Israel. N. Engl. J. Med. 2022, 386, 1712–1720. [Google Scholar] [CrossRef]
- Goldberg, Y.; Mandel, M.; Bar-On, Y.M.; Bodenheimer, O.; Freedman, L.; Haas, E.J.; Milo, R.; Alroy-Preis, S.; Ash, N.; Huppert, A. Waning Immunity after the BNT162b2 Vaccine in Israel. N. Engl. J. Med. 2021, 385, e85. [Google Scholar] [CrossRef]
- Canetti, M.; Barda, N.; Gilboa, M.; Indenbaum, V.; Asraf, K.; Gonen, T.; Weiss-Ottolenghi, Y.; Amit, S.; Doolman, R.; Mendelson, E.; et al. Six-Month Follow-up after a Fourth BNT162b2 Vaccine Dose. N. Engl. J. Med. 2022, 387, 2092–2094. [Google Scholar] [CrossRef]
- Mungmunpuntipantip, R.; Wiwanitkit, V. Expected response to the additional fifth dose of COVID-19 vaccine. Int. J. Prev. Med. 2023, 14, 112. [Google Scholar] [CrossRef] [PubMed]
- Untipantip, R.M.; Wiwanitkit, V. Expected Additional Protection Rate against Omicron COVID-19 Infection and Death for the Fifth Dose of COVID-19 Vaccine: An Appraisal from an Endemic Area in Indochina. J. Sci. Soc. 2024, 51, 72–75. [Google Scholar] [CrossRef]
- Stirrup, O.; Shrotri, M.; Adams, N.L.; Krutikov, M.; Azmi, B.; Monakhov, I.; Tut, G.; Moss, P.; Hayward, A.; Copas, A.; et al. Effectiveness of successive booster vaccine doses against SARS-CoV-2 related mortality in residents of long-term care facilities in the VIVALDI study. Age Ageing 2023, 52, afad141. [Google Scholar] [CrossRef] [PubMed]
- Crotty, S. Hybrid immunity. Science 2021, 372, 1392–1393. [Google Scholar] [CrossRef]
- Kusunoki, H.; Ohkusa, M.; Iida, R.; Saito, A.; Kawahara, M.; Ekawa, K.; Kato, N.; Motone, M.; Shimizu, H. Increase in antibody titer and change over time associated with severe acute respiratory syndrome coronavirus 2 infection after MRNA vaccination: Consideration of the significance of additional vaccination. Clin. Case Rep. 2024, 12, e8953. [Google Scholar] [CrossRef]
- Epsi, N.J.; Richard, S.A.; Lindholm, D.A.; Mende, K.; Ganesan, A.; Huprikar, N.; Lalani, T.; Fries, A.C.; Maves, R.C.; E Colombo, R.; et al. Understanding “Hybrid Immunity”: Comparison and Predictors of Humoral Immune Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) Vaccines. Clin. Infect. Dis. 2023, 76, e439–e449. [Google Scholar] [CrossRef]
- Kusunoki, H. COVID-19 and the COVID-19 Vaccine in Japan—A Review from a General Physician’s Perspective. Pharmacoepidemiology 2023, 2, 188–208. [Google Scholar] [CrossRef]
Total N | 162 | ||
Age, median (IQR) | 69 (65–74) | ||
Sex, N/total (%) | |||
Female | 78/162 (62%) | ||
Male | 47/162 (38%) | ||
Comorbidities, N/total (%) * | |||
Hypertension | 41/125 (33%) | ||
Dyslipidemia | 58/125 (46%) | ||
Cancer | 8/125 (6%) | ||
Diabetes | 17/125 (14%) | ||
Ischemic heart disease | 9/125 (7%) | ||
Rheumatologic disease | 4/125 (3%) | ||
Any comorbidity | 76/125 (61%) | ||
Vaccine Dose ** | Pre-Vaccine | Post-Vaccine | Mean Fold-Change |
sCOVG index (SD) | sCOVG index (SD) | (SD) | |
Third dose | 3.4 (2.9) | 94.9 (1.3) | 29.2 (2.6) |
Fourth dose | 34.2 (2.7) | 97.8 (1.1) | 3.8 (2.4) |
Fifth dose | 65.0 (2.6) | 96.4 (1.2) | 3.6 (3.0) |
Total N | 51 * |
Early adverse events, N/total (%) | |
Mild local pain | 28/51 (55%) |
Local erythema | 8/51 (16%) |
Swelling | 5/51 (10%) |
Movement-restricting pain | 3/51 (6%) |
Late adverse events (after 48 h), N/total (%) | |
No symptoms | 36/51 (71%) |
Weakness or fatigue | 9/51 (18%) |
Arthralgia or myalgia | 4/51 (8%) |
Dizziness | 3/51 (6%) |
Fever | 3/51 (6%) |
Headache | 3/51 (6%) |
Symptom severity compared to previous doses, N/total (%) | |
Similar degree | 35/51 (69%) |
Less severe | 10/51 (20%) |
More severe | 3/51 (6%) |
Do not remember | 3/51 (6%) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Saiag, E.; Gamzu, R.; Padova, H.; Paran, Y.; Goldiner, I.; Cohen, N.; Bomze, D. Antibody Response After a Fifth Dose (Third Booster) of BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers. J. Clin. Med. 2024, 13, 6538. https://doi.org/10.3390/jcm13216538
Saiag E, Gamzu R, Padova H, Paran Y, Goldiner I, Cohen N, Bomze D. Antibody Response After a Fifth Dose (Third Booster) of BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers. Journal of Clinical Medicine. 2024; 13(21):6538. https://doi.org/10.3390/jcm13216538
Chicago/Turabian StyleSaiag, Esther, Ronni Gamzu, Hagit Padova, Yael Paran, Ilana Goldiner, Neta Cohen, and David Bomze. 2024. "Antibody Response After a Fifth Dose (Third Booster) of BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers" Journal of Clinical Medicine 13, no. 21: 6538. https://doi.org/10.3390/jcm13216538
APA StyleSaiag, E., Gamzu, R., Padova, H., Paran, Y., Goldiner, I., Cohen, N., & Bomze, D. (2024). Antibody Response After a Fifth Dose (Third Booster) of BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers. Journal of Clinical Medicine, 13(21), 6538. https://doi.org/10.3390/jcm13216538